Overview

ANRS HB07 IP-Cure-B Proof of Concept (PoC) Clinical Trial. Educating the Liver Immune Environment Through TLR8 Stimulation Followed by NUC Discontinuation

Status:
Not yet recruiting

Trial end date:
2024-06-30

Target enrollment:

Participant gender:

Summary

The ANRS HB07 IP-cure-B study is a proof of concept Phase II clinical trial in HBeAg negative virally suppressed non-cirrhotic CHB patients. It will explore whether stopping NUC or stopping NUC after SLGN administration can increase the rate of HBsAg decline compared to standard of care CHB treatment.

Phase:

Phase 2

Details

Lead Sponsor:

ANRS, Emerging Infectious Diseases

Collaborator:

EUCLID Clinical Trial Platform